Cardiotoxicity in childhood cancer survivors: Strategies for prevention and management

Future Cardiology

Volumn 8, Issue 4, 2012, Pages 647-670

  Harake, Danielle ^a   Franco, Vivian I ^a   Henkel, Jacqueline M ^a   Miller, Tracie L ^a,b   Lipshultz, Steven E ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

anthracycline; cardiotoxicity; childhood cancer survivors; late effects; monitoring; prevention; risk factors

Indexed keywords

ACETYLCYSTEINE; ADIPONECTIN; AMIFOSTINE; ANTHRACYCLINE; CARDIOLIPIN; CARVEDILOL; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; ERYTHROPOIETIN; PREDNISOLONE; PROBUCOL; RAZOXANE; SILDENAFIL; VALSARTAN; VINCRISTINE;

ADD ON THERAPY; ADULTHOOD; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CANCER SURVIVOR; CARDIOTOXICITY; CARDIOVASCULAR RISK; CHILDHOOD CANCER; DRUG EFFICACY; DRUG SAFETY; EXERCISE TEST; HEART FUNCTION; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; NONHUMAN; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SURVIVAL RATE; VASODILATATION;

ADIPONECTIN; AGE FACTORS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTIOXIDANTS; CARBAZOLES; CARDIOLIPINS; CARDIOTONIC AGENTS; DOXORUBICIN; ERYTHROPOIETIN; HEART; HEART DISEASES; HUMANS; LIPID PEROXIDATION; LIPOSOMES; NEOPLASMS; PIPERAZINES; PROPANOLAMINES; PURINES; RAZOXANE; RISK FACTORS; SULFONES; SURVIVORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84864834120     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.12.44     Document Type: Review

References (191)

1. Mariotto AB, Rowland JH, Yabroff KR et al. Long-term survivors of childhood cancers in the United States. Cancer Epidemiol. Biomarkers Prev. 18, 1033-1040 (2009).
2. Hinkle AS, Proukou C, French CA et al. A clinic-based, comprehensive care model for studying late effects in long-term survivors of pediatric illnesses. Pediatrics 113(Suppl. 4), 1141-1145 (2004).
3. Reulen RC, Winter DL, Frobisher C et al. Long-term cause-specific mortality among survivors of childhood cancer. JAMA 304(2), 172-179 (2010).
4. Mulrooney DA, Yeazel MW, Kawashima T et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the Childhood Cancer Survivor study cohort. BMJ 339, b4606 (2009).
5. Van Der Pal HJ, Van Dalen EC, Van Delden E et al. High risk of symptomatic cardiac events in childhood cancer survivors. J. Clin. Oncol. 30(13), 1429-1437 (2012).
6. Lipshultz SE, Adams MJ. Cardiotoxicity after childhood cancer: Beginning with the end in mind. J. Clin. Oncol. 28(8), 1276-1281 (2010).
7. Hudson MM, Mertens AC, Yasui Y et al. Health status of adult long-term survivors of childhood cancer: A report from the childhood cancer survivor study. JAMA 290(12), 1583-1592 (2003).
8. Mody R, Li S, Dover DC et al. Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor study. Blood 111(12), 5515-5523 (2008).
9. Miller TL, Lipsitz SR, Lopez-Mitnik G et al. Characteristics and determinants of adiposity in pediatric cancer survivors. Cancer Epidemiol. Biomarkers Prev. 19(8), 2013-2022 (2010).
10. National Research Council. Chapter 4: Late effects of childhood cancer. In: CHILDHOOD Cancer Survivorship: IMPROVING Care and Quality of Life. Hewitt M, Weiner SL, Simone JV (Eds). National Academic Press, DC, USA, 48-49 (2003).
11. Alvarez JA, Scully RE, Miller TL et al. Long-term effects of treatments for childhood cancers. Curr. Opin. Pediatr. 19, 23-31 (2007).
12. Van Dalen EC, Raphaël MF, Caron HN, Kremer LC. Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer. Cochrane Database Syst. Rev. 1, CD006647 (2009).
13. Fulbright JM, Huh W, Anderson P, Chandra J. Can anthracycline therapy for pediatric malignancies be less cardiotoxic? Curr. Oncol. Rep. 12(6), 411-419 (2010).
14. Herman EH, Ferrans VJ, Jordan W, Ardalan B. Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits. Res. Commun. Chem. Pathol. Pharmacol. 31(1), 85-97 (1981).
15. Herman EH, el-Hage AN, Ferrans VJ, Ardalan B. Comparison of the severity of the chronic cardiotoxicity produced by doxorubicin in normotensive and hypertensive rats. Toxicol. Appl. Pharmacol. 78(2), 202-214 (1985).
16. Outomuro D, Grana DR, Azzato F, Milei J. Adriamycin-induced myocardial toxicity: New solutions for an old problem? Int. J. Cardiol. 117(1), 6-15 (2007).
17. Mordente A, Meucci E, Martorana GE, Giardina B, Minotti G. Human heart cytosolic reductases and anthracycline cardiotoxicity. IUBMB Life 52, 83-88 (2001).
18. Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE. Protecting against anthracycline-induced myocardial damage: A review of the most promising strategies. Br. J. Haematol. 131(5), 561-578 (2005).
19. Gianni L, Zweier JL, Levy A, Myers CE. Characterization of the cycle of iron-mediated electron transfer from adriamycin to molecular oxygen. J. Biol. Chem. 260(11), 6820-6826 (1985).
20. Olson RD, Mushlin PS. Doxorubicin cardiotoxicity: Analysis of prevailing hypothesis. FASEB J. 4(13), 3076-3086 (1990).
21. Milei J, Boveris A, Llesuy S et al. Amelioration of adriamycin-induced cardiotoxicity in rabbits by prenylamine and vitamins A and E. Am. Heart J. 111, 95-102 (1986).
22. Ferrero ME, Ferrero E, Gaja U. Adriamycin: Energy metabolism and mitochondrial oxidations in the heart of treated rabbits. Biochem. Pharmacol. 25(2), 125-130 (1976).
23. Earm YE, Ho WK, So I. Effects of adriamycin on ionic currents in single cardiac myocytes of the rabbit. J. Mol. Cell. Cardiol. 26(2), 163-172 (1994).
24. Olson RD, Li X, Palade P et al. Sarcoplasmic reticulum calcium release is stimulated and inhibited by daunorubicin and daunorubicinol. Toxicol. Appl. Pharmacol. 169(2), 168-176 (2000).
25. Gozalvez M, Blanco M. Inhibition of NA-K ATPase by the antitumor antibiotic adriamycin. 5th International Biophysics Congress, Copenhagen. Cancer Res. 39(1), 257-261 (1979).
26. Lou H, Danelisen I, Singal PK. Cytokines are not upregulated in adriamycin-induced cardiomyopathy and heart failure. J. Mol. Cell. Cardiol. 36(5), 683-690 (2004).
27. Lenaz L, Page JA. Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat. Rev. 3(3), 111-120 (1976).
28. Lipshultz SE, Rusconi P, Scully RE. Chapter 18: Assessment of cardiotoxicity during anti-cancer therapy. In: nt-proBNP as a Biomarker in Cardiovascular Diseases. Januzzi JL, Bayes-Genis A (Eds). Prous Science SA, Barcelona, Spain, 193-198 (2007).
29. Pointon AV, Walker TM, Phillips KM et al. Doxorubicin in vivo rapidly alters expression and translation of myocardial electron transport chain genes, leads to ATP loss and caspase 3 activation. PLoS ONE 5(9), e12733 (2010).
30. Gonzalvez F, Gottlieb E. Cardiolipin: Setting the beat of apoptosis. Apoptosis 12(5), 877-885 (2007).
31. Goormaghtigh E, Brasseur R, Huart P, Ruysschaert JM. Study of the adriamycin cardiolipin complex structure using attenuated total reflection infrared spectroscopy. Biochemistry 26(6), 1789-1794 (1987).
32. Garcia Fernandez M, Troiano L, Moretti L. Early changes in intramitochondrial cardiolipin distribution during apoptosis. Cell Growth Differ. 13(9), 449-455 (2002).
33. Aguilar L, Ortega-Pierres G, Campos B et al. Phospholipid membranes form specific nonbilayer molecular arrangements that are antigenic. J. Biol. Chem. 274(36), 25193-25196 (1999).
34. Vlasova II, Tyurin VA, Kapralov AA et al. Nitric oxide inhibits peroxidase activity of cytochrome C cardiolipin complex and blocks cardioliopin oxidation. J. Biol. Chem. 281(21), 14554-14562 (2006).
35. Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinen M, Voipio-Pulkki LM. Acute doxorubicin cardiotoxicity involves cardiomyocte apoptosis. Cancer Res. 60(7), 1789-1792 (2000).
36. Zhang YQ, Shi J, Li YJ, Wei L. Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch. Immunol. Ther. Exp. 57(6), 435-445 (2009).
37. Adams MJ, Lipshultz SE. Pathophysiology of anthracycline-and radiation-associated cardiomyopathies: Implications for screening and prevention. Pediatr. Blood Cancer 44(7), 600-606 (2005).
38. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N. Engl. J. Med. 324(12), 808-815 (1991).
39. Sorensen K, Levitt G, Bull C, Chessells J, Sullivan I. Anthracycline dose in childhood acute lymphoblastic leukemia: Issues of early survival versus late cardiotoxicity. J. Clin. Oncol. 15(1), 61-68 (1997).
40. Giantris A, Abdurrahman L, Hinkle A et al. Anthracycline-induced cardiotoxicity in children and young adults. Crit. Rev. Oncol. Hematol. 27, 53-68 (1998).
41. Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: Alterations produced by doxorubicin. J. Clin. Invest. 65(1), 128-135 (1980).
42. Cascales A, Sanchez-Vega B, Navarro N, Pastor-Quirante F, Corral J, Vicente V, De La Pena FA. Clinical and genetic determinants of anthracycline-induced cardiac iron accumulation. Int. J. Cardiol. 154(3), 282-286 (2010).
43. Arai M, Yoguchi A, Takizawa T et al. Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca2+-ATPase gene transcription. Circ. Res. 86(1), 8-14 (2000).
44. Jeyaseelan R, Poizat C, Wu HY, Kedes L. Molecular mechanisms of doxorubicin-induced cardiomyopathy. Selective suppression of Reiske iron-sulfur protein, ADP/ATP translocase, and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes. J. Biol. Chem. 272(9), 5828-5832 (1997).
45. Lebrecht DMS, Setzer B, Ketelsen UP, Haberstroh J, Walker UA. Time-dependant and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation 108(19), 2423-2429 (2003).
46. Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinen M, Voipio-Pulkki LM. Acute doxorubicin cardiotoxicity involves cardiomyocte apoptosis. Cancer Res. 60(7), 1789-1792 (2000).
47. Childs AC, Phaneuf SL, Dirks AJ, Phillips T, Leeuwenburgh C. Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Res. 62(16), 4592-4598 (2002).
48. Von Hoff DD, Layard M, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 91(5), 710-717 (1979).
49. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 97(11), 2869-2879 (2003).
50. Van Dalen EC, Van Der Pal HJ, Kok WE, Caron HN, Kremer LC. Clinical heart failure in a cohort of children treated with anthracyclines: A long-term follow-up study. Eur. J. Cancer 42(18), 3191-3198 (2006).
51. Van Der Pal HJ, Van Dalen EC, Hauptmann M et al. Cardiac function in 5 year survivors of childhood cancer: A long-term follow-up study. Arch. Intern. Med. 170(14), 1247-1255 (2010).
52. Blanco JG, Sun CL, Landier W et al. Anthracycline-related cardiomyopathy after childhood cancer: Role of polymorphisms in carbonyl reductase genes - A report from the Children's Oncology Group. J. Clin. Oncol. 30(13), 1415-1421 (2012).
53. Van Dalen EC, Caron HN, Dickinson HO, Kremer LCM. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst. Rev. 25(1), CD003917. Update in: COCHRANE Database Syst. Rev. 2011(6), CD003917 (2005).
54. Lipshultz SE, Lipsitz SR, Sallen SE et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J. Clin. Oncol. 23(12), 2629-2636 (2005).
55. Davies SM. Getting to the heart of the matter. J. Clin. Oncol. 30(13), 1399-1400 (2012).
56. Visscher H, Ross CJD, Rassekh SR et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J. Clin. Oncol. 30(13), 1422-1428 (2012).
57. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The Pediatric Oncology Group experience. J. Clin. Oncol. 15, 1544-1552 (1997).
58. Sorensen K, Levitt GA, Bull C, Dorup I, Sullivan ID Late anthracycline cardiotoxicity after childhood cancer: A prospective longitudinal study. Cancer 97(8), 1991-1998 (2003).
59. Nysom K, Holm K, Lipsitz SR et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J. Clin. Oncol. 2, 545-550 (1998).
60. Lipshultz SE, Lipsitz SR, Mone SM et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N. Engl. J. Med. 332(26), 1738-1743 (1995).
61. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266(12), 1672-1677 (1991).
62. Anderlini P, Bengamin RS, Wong FC et al. Idarubicin cardiotoxicity: A retrospective study in acute myeloid leukemia and myelodysplasia. J. Clin. Oncol. 13(11), 2827-2834 (1995).
63. Sorensen K, Levitt G, Sebag-Montefiore D, Bull C, Sullivan I. Cardiac function in Wilms' tumor survivors. J. Clin. Oncol. 13(7), 1546-1556 (1995).
64. Nysom K, Colan DC, Lipshultz SE. Late cardiotoxicity following anthracycline therapy for childhood cancer. Prog. Pediatr. Cardiol. 8, 121-138 (1998).
65. Green DM, Grigoriev YA, Nan B et al. Congestive heart failure after treatment for Wilms' tumor: A report from the National Wilms' Tumor Study Group. J. Clin. Oncol. 19(7), 1926-1934 (2001).
66. Kremer LCM, Van Dalen EC, Offringa M, Ottenkamp J, Voûte PA. Anthracycline-induced clinical heart failure in a cohort of 607 children: Long-term follow-up study. J. Clin. Oncol. 19(1), 191-196 (2001).
67. Tukenova M, Guibout C, Oberlin O et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J. Clin. Oncol. 28(8), 1308-1315 (2010).
68. Rodvold KA, Rushing DA, Tewksbury DA. Doxorubicin clearance in the obese. J. Clin. Oncol. 6(8), 1321-1327 (1998).
69. Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Harrison DC. Early anthracycline cardiotoxicity. Am. J. Med. 65(5), 823-832 (1978).
70. Lipshultz SE, Miller TM, Scully RE et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: Associations with long-term echocardiographic outcomes. J. Clin. Oncol. 30(10), 1042-1049 (2012).
71. Ali MK, Ewer MS, Gibbs HR, Swafford J, Graff KL. Late doxorubicin-associated cardiotoxicity in children. The possible role of intercurrent viral infection. Cancer 74(1), 182-188 (1994).
72. Tolba KA, Deliargyris EN. Cardiotoxicity of cancer therapy. Cancer Invest. 17(6), 408-422 (1999).
73. Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 94(4), 525-533 (2008).
74. Grenier MA, Lipshultz ME. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin. Oncol. 25(4 Suppl. 10), 72-85 (1998).
75. Simbre VC, Duffy SA, Dadlani GH, Miller TL, Lipshultz SE. Cardiotoxicity of cancer chemotherapy: Implications for children. Paediatr. Drugs 7, 187-202 (2005).
76. Barry E, Alvarez JA, Scully RE, Miller TL, Lipshultz SE. Anthracycline-induced cardiotoxicity: Course, pathophysiology, prevention and management. Expert Opin. Pharmacother. 8, 1039-1058 (2007).
77. Herman EH, Zhang J, Lipshultz SE et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J. Clin. Oncol. 17, 2237-2243 (1999).
78. Lipshultz SE, Sanders SP, Goorin AM, Krischer JP, Sallan SE, Colan SD. Monitoring for anthracycline cardiotoxicity. Pediatrics 93, 433-437 (1994).
79. Carver JR, Shapiro CL, NG A et al. ASCO Cancer Survivorship Exert Panel. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: Cardiac and pulmonary late effects. J. Clin. Oncol. 25, 3991-4008 (2007).
80. Steinhertz LJ, Graham T, Hurwitz R et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: REPORT of the cardiology committee of the Children's Cancer Study Group. Pediatrics 89, 942-949 (1992).
81. Lipshultz S.E. Sanders S.P. Colan S.D. Goorin A.M. Sallan S.E. Krischer J.P.,(1994) Letter to the Editor, Pediatrics 94, 781.
82. Lipshultz SE, Sanders SP, Colan SD, Goorin AM, Sallan SE, Krischer JP. Letter to the Editor. Pediatrics 94, 781 (1994) 82. Adams MJ, Lipshultz SE, Schwartz C, Fajardo LF, Coen V, Constine LS. Radiation-associated cardiovascular disease: Manifestations and management. Semin. Radiat. Oncol. 13(3), 346-356 (2003).
83. Adams MJ, Hardenbergh PH, Constine LS, Lipshultz SE. Radiation-associated cardiovascular disease. Crit. Rev. Oncol. Hematol. 45(1), 55-75 (2003).
84. Lipshultz SE, Rifai N, Dalton VM et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N. Engl. J. Med. 351(2), 145-153 (2004).
85. Ganame J, Claus P, Eyskens B et al. Acute cardiac functional and morphological changes after anthracycline infusions in children. Am. J. Cardiol. 99(7), 974-977 (2007).
86. Ganame J, Claus P, Uyttebroeck A et al. Myocardial dysfunction late after low-dose anthracycline treatment in asymptomatic pediatric patients. J. Am. Soc. Echocardiogr. 20(12), 1351-1358 (2007).
87. Colan SD, Borrow KM, Neuman A. Left ventricular end-systolic wall stress-velocity of fiber shortening relation: A load independent index of myocardial contractility. J. Am. Coll. Cardiol. 4, 715-724 (1984).
88. Lipshultz SE, Colan SD. The use of echocardiography and holter monitoring in the assessment of anthracycline-treated patients. In: CARDIAC Toxicity After Treatment for Childhood Cancer. Wiley-Liss, NY, USA, 45-62 (1993).
89. Mitani I, Jain D, Joska TM, Burtness B, Zaret BL. Doxorubicin cardiotoxicity: PREVENTION of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J. Nucl. Cardiol. 10(2), 132-139 (2003).
90. Glanzmann C, Huguenin P, Lutolf UM, Maire R, Jenni R, Gumppenberg V. Cardiac lesions after mediastinal radiation for Hodgkin's disease. Radiother. Oncol. 30(1), 43-54 (1994).
91. Lipshultz SE, Rifai N, Sallan SE et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 96(8), 2641-2648 (1997).
92. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N. Engl. J. Med. 339(5), 321-328 (1998).
93. Cowie MR, Mendez GF. BNP and congestive heart failure. Prog. Cardiovasc. Dis. 44(4), 293-321 (2002).
94. Linssen GC, Bakker SJ, Voors AA et al. N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. Eur. Heart J. 31(1), 120-127 (2010).
95. Bibbins-Domingo K, Gupta R, Na B et al. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA 297, 169-176 (2007).
96. Trachtenberg BH, Landy DC, Franco VI et al. Anthracycline-associated cardiotoxicity in survivors of childhood cancer. Pediatr. Cardiol. 32, 342-353 (2011).
97. Franco VI, Henkel JM, Miller TL, Lipshultz SE. Cardiovascular effects in childhood cancer survivors treated with anthracyclines. Cardiol. Res. Pract. 10, 134679 (2011).
98. Schwartz CL, Hobbie WL, Truesdell S, Constine LC, Clark EB. Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer. J. Clin. Oncol. 11(10), 1906-1910 (1993).
99. Larsen RL, Barber G, Heise CT, August CS. Exercise assessment of cardiac function in children and young adults before and after bone marrow transplantation. Pediatrics 89(4 Pt 2), 722-729 (1992).
100. Weesner KM. Exercise echocardiography in the detection of anthracycline cardiotoxicity. Cancer 68(2), 435-438 (1991).
101. Adams MJ, Lipsitz SR, Colan SD et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J. Clin. Oncol. 22(15), 3139-3148 (2004).
102. Hogenhuis J, Jaarsma T, Voors AA, Hillege HL, Lesman I, Van Veldhuisen DJ. Correlates of B-type natriuretic peptide and 6-min walk in heart failure patients. Int. J. Cardiol. 108(1), 63-67 (2006).
103. Ryberg M, Nielsen D, Skovsgaard T, Hansen J, Jensen BV, Dombernowsky P. Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer. J. Clin. Oncol. 16(11), 3502-3508 (1998).
104. Legha SS, Benjamin RS, Mackay B et al. Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer. Cancer 49(9), 1762-1766 (1982).
105. Hortobagyi GN, Frye D, Buzdar AU et al. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer 63(1), 37-45 (1989).
106. Shapira J, Gotfried M, Lishner M, Ravid M. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regiment. A prospective evaluation. Cancer 65(4), 870-873 (1990).
107. Lipshultz SE, Giantris AL, Lipsitz SR et al. Doxorubicin administration by continuous infusion is not cardioprotective: The Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J. Clin. Oncol. 20(6), 1677-1682 (2002).
108. Levitt GA, Dorup I, Sorensen K, Sullivan I. Does anthracycline administration by infusion in children affect late cardiotoxicity? Br. J. Haematol. 24(4), 463-468 (2004).
109. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. 339(13), 900-905 (1998).
110. Weiss RB. The anthracyclines: Will we ever find a better doxorubicin? Semin. Oncol. 19(6), 670-686 (1992).
111. Ganzina F 4́-epi-doxorubicin, a new analogue of doxorubicin: A preliminary overview of preclinical and clinical data. Cancer Treat. Rev. 10(1), 1-22 (1983).
112. Lahtinen R, Kuikka J, Nousiainene T, Uusituoa M, Lansimies E. Cardiotoxicity of epirubicin and doxorubicin: A double-blind randomized study. Eur. J. Haematol. 46(5), 301-305 (1991).
113. Cottin Y, Touzery C, Dalloz F et al. Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: Evolution of the diastolic and systolic parameters studies by radionuclide angiography. Clin. Cardiol. 21(9), 665-670 (1998).
114. Dorr RT, Shipp NG, Lee KM. Comparison of cytotoxicity in heart cells and tumor cells exposed to DNA intercalating agents in vitro. Anticancer Drugs 2(1), 27-33 (1991).
115. Alderton PM, Gross J, Green MD. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Res. 52(1), 194-201 (1992).
116. Herman EH, Zhang J, Hasinoff BB, Clark JRJ, Ferrans VJ. Comparison of the structural changes induced by doxorubicin and mitoxantrone in the heart, kidney and intestine and characterization of the Fe(III)-mitoxantrone complex. J. Mol. Cell. Cardiol. 29(9), 2415-2430 (1997).
117. Creutzig U, Ritter J, Zimmermann M et al. Idarubicin improves blast cell clearance during induction therapy in children with AML: Results of study AML-BFM 93. AML-BFM Study Group. Leukemia 15(3), 348-354 (2001).
118. Tardi PG, Boman NL, Cullis PR. Liposomal doxorubicin. J. Drug Target. 4(3), 129-140 (1996).
119. Batist G, Ramakrishnan G, Rao CS et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol. 19(5), 1444-1454 (2001).
120. Harris L, Batist G, Belt R et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multi-center trial as first-line therapy of metastatic breast carcinoma. Cancer 94(1), 25-36 (2002).
121. Safra T. Cardiac safety of liposomal anthracyclines. Oncologist 8(2), 17-24 (2003).
122. Gabizon AA. Liposomal anthracyclines. Hematol. Oncol. Clin. North Am. 8(2), 431-450 (1994).
123. Money-Kyrle JF, Bates F, Ready J, Gazzard BG, Phillips RH, Boag FC. Liposomal daunorubicin in advanced Kaposi's sarcoma: A Phase II study. Clin. Oncol. (R. Coll. Radiol.) 5(6), 367-371 (1993).
124. Gill PS, Wernz J, Scadden DT. Randomized Phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 14(8), 2353-2364 (1996).
125. O'Brien ME, Wigler N, Inbar M et al. Reduced cardiotoxicity and comparable efficacy in a Phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 15(3), 440-449 (2004).
126. Sieswerda E, Kremer LC, Caron HN, Van Dalen EC: THE use of liposomal anthracycline analogues for childhood malignancies: A systematic review. Eur. J. Cancer 47(13), 2000-2008 (2011).
127. Zimethbaum P, Eder H, Frishman W. Probucol: Pharmacology and clinical application. J. Clin. Pharmacol. 30(1), 3-9 (1990).
128. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: Evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc. Natl Acad. Sci. USA 84(21), 7725-7729 (1987).
129. Kuzuya M, Kuzuya F. Probucol as an antioxidant and antiatherogenic drug. Free Radic. Biol. Med. 14(1), 67-77 (1993).
130. Siveski-Iliskovic N, Hill M, Chow DA, Singhal PK. Probucol protects against doxorubicin cardiomyopathy without interfering with its antitumor effect. Circulation 91(1), 10-15 (1995).
131. Singal PK, Deally CM, Weinberg LE. Subcellular effects of doxorubicin in the heart. A concise review. J. Mol. Cell. Cardiol. 19(8), 817-828 (1987).
132. Iliskovic N, Singal PK. Lipid lowering: An important factor in preventing doxorubicin-induced heart failure. Am. J. Pathol. 150(2), 727-734 (1997).
133. Iliskovic N, Hasinoff BB, Malisza KL, Li T, Danelisen I, Singal PK. Mechanisms of beneficial effects of probucol in doxorubicin cardiomyopathy. Mol. Cell. Biochem. 196(1-2), 43-49 (1999).
134. Li T, Danelisen I, Bello-Klein A, Singal PK. Effects of probucol on changes of antioxidant enzymes in doxorubicin-induced cardiomyopathy in rats. Cardiovasc. Res. 46(3), 523-530 (2000).
135. Li T, Singal PK. Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol. Circulation 102(17), 2105-2110 (2000).
136. De Flora S, Bennicelli C, Serra D, Izzotti A, Cesarone CF. Role of glutathione and N-acetylcysteine on the mutagenicity and carcinogenesis. In: ABSORPTION and Utilization of Amino Acids (Volume 3). Friedman M (Ed.). CRC Press, FL, USA, 19-53 (1989).
137. Myers CE, Bonow R, Palmeri S et al. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin. Oncol. 10(1), 53-55 (1983).
138. Frishman WH. Carvedilol. Drug Therapy 339(24), 1759-1765 (1998).
139. Yue TL, Cheng HY, Lysko PG et al. Carvedilol, a new vasodilator and beta adrenoreceptor antagonist, is an antioxidant and free radical scavenger. J. Pharmacol. Exper. Therap. 263(1), 92-98 (1992).
140. Feuerstein GZ, Ruffolo RR Jr. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur. Heart J. 16, 38-42 (1995).
141. Noguchi N, Nishino K, Niki E. Antioxidant action of the antihypertensive drug carvedilol, against lipid peroxidation. Biochem. Pharmacol. 59(9), 1069-1076 (2000).
142. Matsui H, Morishima I, Numaguchi Y, Toki Y, Okumura K, Hayakawa T. Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. Life Sci. 65(12), 1265-1274 (1999).
143. Fazio S, Palmieri EA, Ferravante B, Bone F, Biondi B, Sacca L. Doxorubicin-induced cardiomyopathy treated with carvedilol. Clin. Cardiol. 21(10), 777-779 (1998).
144. Spallarossa P, Garibaldi S, Altieri P et al. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J. Mol. Cell. Cardiol. 37(4), 837-846 (2004).
145. Nakamae H, Tsumura K, Terada Y et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 104(11), 2492-2498 (2005).
146. Tokudome T, Mizushige K, Noma T et al. Prevention of doxorubicin (adriamycin)-induced cardiomyopathy by simultaneous administration of angiotensin-converting enzyme inhibitor assessed by acoustic densitometry. J. Cardiovasc. Pharmacol. 36(3), 361-368 (2000).
147. Fischer PW, Salloum F, Das A, Hyder H, Kukreja RC. Phosphodiesterase-5 inhibition with Sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 111(13), 1601-1610 (2005).
148. Hanley PJ, Dröse S, Brandt U et al. 5-hydroxydecanoate is metabolised in mitochondria and creates a rate-limiting bottleneck for beta-oxidation of fatty acids. J. Physiol. 562(2), 307-318 (2005).
149. Di X, Gennings C, Bear HD et al. Influence of the phosphodiesterase-5 inhibitor, Sildenafil, on sensitivity to chemotherapy in breast tumor cells. Breast Cancer Res. Treat. 124(2), 349-360 (2010).
150. Essayan DM. Cyclic nucleotide phosphodiesterases. J. Allergy Clin. Immunol. 108(5), 671-680 (2001).
151. Asmis R, Wang Y, Xu L, Ksgati M, Begley JG, Mieyal JJ. A novel thiol oxidation-based mechanism for adriamycin-induced cell injury in human macrophages. FASEB J. 19(13), 1866-1868 (2005).
152. Li W, Lam MS, Birkeland A et al. Cell-based assays for profiling activity and safety properties of cancer drugs. J. Pharmacol. Toxicol. Methods. 54(3), 313-319 (2006).
153. Raja SG, Danton MD, MacArthur, KJ, Pollock JC. Effects of escalating doses of sildenafil on hemodynamics and gas exchange in children with pulmonary hypertension and congenital cardiac defects. J. Cardiothorac. Vasc. Anesth. 21(2), 203-207 (2007).
154. Karatza AA, Bush A, Magee AG. Safety and efficacy of sildenafil therapy in children with pulmonary hypertension. Int. J. Cardiol. 100(2), 267-273 (2005).
155. Baquero H, Soliz A, Neira F, Venegas ME, Sola A. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: A pilot randomized blinded study. Pediatrics 117(4), 1077-1083 (2006).
156. Juliana AE, Abbad FCB. Severe persistent pulmonary hypertension of the newborn in a setting where limited resources exclude the use of inhaled nitric oxide: Successful treatment with sildenafil. Eur. J. Pediatr. 164(10), 626-629 (2005).
157. Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur. J. Endocrinol. 148(3), 293-300 (2003).
158. Konishi M, Haraguchi G, Ohigashi H et al. Adiponectin protects against doxorubicin-induced cardiomyopathy by anti-apoptotic effects through AMPK upregulation. Cardiovasc. Res. 89(2), 309-319 (2011).
159. Li L, Takemura G, Li Y et al. Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation 113(4), 535-543 (2006).
160. Hasinoff BB. The interaction of the cardioprotective agent ICRF-187 [+)-1, 2-bis(3, 5 dioxopiperazinyl-1-yL)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of doxorubicin. Agents Actions 26(3-4), 378-385 (1989).
161. Speyer JL, Green MD, Zeleniuch-Jacquotte A et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J. Clin. Oncol. 10(1), 117-127 (1992).
162. Swain SM, Whaley FS, Gerber MC, Ewer MS, Bianchine JR, Gams RA. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J. Clin. Oncol. 15(4), 1333-1340 (1997).
163. Wexler LH, Andrich MP, Venzon D et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J. Clin. Oncol. 14(2), 362-372 (1996).
164. Swain SM, Whaley FS, Gerber MC et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J. Clin. Oncol. 15(4), 1318-1332 (1997).
165. Lopez M, Vici P, Di Lauro L et al. Randomized prospective clinical trial to evaluate cardioprotection of dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J. Clin. Oncol. 16(1), 86-92 (1998).
166. Lipshultz SE, Scully RE, Lipsitz SR et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: Long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 11(10), 950-961 (2010).
167. Tebbi CK, London WB, Friedman D et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J. Clin. Oncol. 25, 493-500 (2007).
168. Herman EH, Zhang J, Rifai N et al. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin-and mitoxantrone-induced cardiotoxicity. Cancer Chemother. Pharmacol. 48(4), 297-304 (2001).
169. Barry EV, Vrooman LM, Dahlberg SE et al. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J. Clin. Oncol. 26, 1106-1111 (2008).
170. Vrooman LM, Neuber DS, Stevenson KE et al. The low incidence of secondary acutemyelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: A report from the Dana-Farber Cancer Institute ALL Consortium. Eur. J. Cancer 47(9), 1373-1379 (2011).
171. Schuchter LM, Hensley ML, Meropol NJ, Winer EP. Update of recommendations for the use of chemotherapy and radiotherapy protectants: Clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. 20(12), 2895-2903 (2002).
172. Yang JL, Fernandes DJ, Speicher L, Capizzi RL. Biochemical determinants of the cytoprotective effect of amifostine. Proc. Am. Cancer Res. 36, 3725 (1995).
173. Calabro-Jones PM, Aguilera JA, Ward JF, Smoluk GD, Fahey RC. Uptake of WR-2721 derivatives by cells in cultures: Identification of the transported form of the drug. Cancer Res. 48(13), 3634-3640 (1988).
174. Nazeyrollas P, Frances C, Prevost A et al. Efficiency of amifostine as a protection against doxorubicin toxicity in rats during a 12 day treatment. Anticancer Res. 23(1A), 405-409 (2003).
175. Dragojevic-Simic VM, Dobric SL, Bokonjic DR et al. Amifostine protection against doxorubicin cardiotoxicity in rats. Anticancer Drugs 15(2), 169-178 (2004).
176. Herman EH, Ferrans VJ. Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (+/-)-1, 2-bis (3, 5-dioxopipreazine-1-yl) propane (ICRF-187). Cancer Res. 41(9 Pt 1), 3436-3440 (1981).
177. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325(5), 293-302 (1991).
178. Haq MM, Legha SS, Choski J et al. Doxorubicin-induced congestive heart failure in adults. Cancer 56(6), 1361-1365 (1985).
179. Redfield MM, Gersh BJ, Bailey KR, Rodeheffer RJ. Natural history of incidentally discovered asymptomatic idiopathic dilated cardiomyopathy. Am. J. Cardiol. 74(7), 737-739 (1994).
180. Sieswerda E, Van Dalen EC, Postma A, Cheuk DK, Caron HN, Kremer LC: MEDICAL interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. Cochrane Database Syst. Rev. 7(9), CD008011 (2011).
181. Lipshultz SE, Vlach SA, Lipsitz SR et al. Cardiac changes associated with growth hormone therapy among children treated with anthracyclines. Pediatrics 115, 1613-1622 (2005).
182. Silber JH, Cnaan A, Clark BJ et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J. Clin. Oncol. 22(5), 820-828 (2004).
183. Lipshultz SE, Lipsitz SR, Sallan SE et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood Cancer J. Clin. Oncol. 20, 4517-4522 (2002).
184. Mertens AC, Sencer S, Myers CD et al. Complementary and alternative therapy use in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor study. Pediatr. Blood Cancer 50, 90-97 (2008).
185. Ibsen S, Zahavy E, Wrasdilo W, Berns M, Chan M, Esener S. A novel doxorubicin prodrug with controllable photolysis activation for cancer chemotherapy. Pharm. Res. 27(9), 1848-1860 (2010).
186. Young K, Hare JM. Stem cells in cardiopulmonary development: IMPLICATIONS for novel approaches to therapy for pediatric cardiopulmonary diseases. Progr. Pediatr. Cardiol. 25(3), 37-49 (2008).
187. Assmus B, Schachinger V, Teupe C et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 106(24), 3009-3017 (2002).
188. Schachinger V, Assmus B, Britten MB et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: Final one-year results of the TOPCARE-AMI trial. J. Am. Coll. Cardiol. 44(8), 1690-1699 (2004).
189. Wollert KC, Meyer GP, Lotz J et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: The BOOST randomized controlled clinical trial. Lancet 364, 10-16 (2004).
190. Meyer GP, Wollert KC, Lotz J et al. Intracoronary bone marrow cell transfer after myocardial infarction: Eighteen months' follow-up data from the randomized, controlled BOOST (BOnemarrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation 113(10), 1287-1294 (2006).
191. Pillekamp F, Reppel M, Brockmeier K, Hescheler J. Stem cells and their potential relevance to paediatric cardiology. Cardiol. Young 16(2), 117-124 (2006).